527 related articles for article (PubMed ID: 27072351)
1. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
2. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
4. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
5. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
6. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract][Full Text] [Related]
7. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas.
Xu RH; Wong ELY; Jin J; Dou Y; Dong D
Eur J Health Econ; 2020 Dec; 21(9):1363-1373. PubMed ID: 32960388
[TBL] [Abstract][Full Text] [Related]
8. A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches.
Khan I; Morris S
Health Qual Life Outcomes; 2014 Nov; 12():163. PubMed ID: 25388439
[TBL] [Abstract][Full Text] [Related]
9. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
10. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
Woodcock F; Doble B;
Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
[TBL] [Abstract][Full Text] [Related]
11. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
[TBL] [Abstract][Full Text] [Related]
12. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
[TBL] [Abstract][Full Text] [Related]
13. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
14. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
15. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
[TBL] [Abstract][Full Text] [Related]
16. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
[TBL] [Abstract][Full Text] [Related]
17. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
18. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
19. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
20. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.
Yang F; Wong CKH; Luo N; Piercy J; Moon R; Jackson J
Eur J Health Econ; 2019 Nov; 20(8):1195-1206. PubMed ID: 31338698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
